Type-B monoamine oxidase inhibitors,encompassing selegiline,rasagiline,and safinamide,are available to treat Parkinson's disease.These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stag...
supported by grants from Jiangsu Provincial Key R&D Program(BE2018658);Suzhou Science and Technology Development Plan(Minsheng Science and Technology)(SKJY2021089);Discipline Construction Program of the Second Affiliated Hospital of Soochow University(XKTJ-XK202001);Gusu Health Talents Plan(GSWS2020035,GSWS2019041).
To the Editor:Parkinson’s disease(PD)is the second most common neurodegenerative disorder,and sleep disturbance is a major disabling non-motor symptom.[1]Excessive daytime sleepiness(EDS)is defined as inappropriate a...
supported by National Natural Science Foundation of China(81373997,U1402221,81573640 and 81603316);Beijing Natural Science Foundation(7161011);Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study(BZ0150);CAMS Innovation Fund for Medical Sciences(CIFMS)(2016-I2M-1-004);Key Research and Development Project of Hunan Province(2015SK2029-1);Scientific Research Foundation of the Higher Education Institutions of Hunan Province(15K091)
OBJECTIVE(1) To estimate the value of the subacute MPTP mouse model in aspects of behavioral performance,biochemical changes and pathological abnormalities.(2) To find effective positive drugs.METHODS Male C57 BL/6 mi...
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model remains the most commonly used animal model of Parkinson's disease (PD). There are three MPTP-treatment schemes: acute, subacute and chronic. Consi...
It has been suggested that in patients with Parkinson’s disease (PD) metabolism of the MAO-B inhibitor selegiline to methamphetamine may contribute and/or exacerbate sleep problems, possibly leading to deficits of co...
The authors’work is supported by the Henry G Leong Endowed Professorship;the Donation Fund for Neurology Research,University of Hong Kong.
There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B(MAOB)inhibitors.They have been studied for their potential disease-modifying e...